Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company NextCure, Inc.

Equities

NXTC

US65343E1082

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 03:47:50 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.315 USD -8.68% Intraday chart for NextCure, Inc. -15.92% +15.79%
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Apr. 04 NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board CI

Business Summary

NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.

Number of employees: 82

Managers

Managers TitleAgeSince
Michael Richman FOU
 Founder 63 15-11-30
Steven Cobourn DFI
 Director of Finance/CFO 61 17-12-31
Han Myint CTO
 Chief Tech/Sci/R&D Officer 71 21-01-13
Timothy Mayer COO
 Chief Operating Officer 59 16-01-31
Solomon Langermann CTO
 Chief Tech/Sci/R&D Officer 64 15-09-30
Kevin Shaw LAW
 General Counsel 50 22-04-30
Sourav Kundu PRN
 Corporate Officer/Principal 64 21-06-30
Sebastien Maloveste PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
David Kabakoff CHM
 Chairman 76 15-11-30
Michael Richman FOU
 Founder 63 15-11-30
Chau Khuong BRD
 Director/Board Member 48 15-11-30
Elaine Jones BRD
 Director/Board Member 69 15-11-30
Stephen Webster BRD
 Director/Board Member 63 19-03-31
Anne Borgman BRD
 Director/Board Member 56 21-09-30
Ellen Feigal BRD
 Director/Board Member 69 21-09-30
John Houston BRD
 Director/Board Member 64 20-09-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,903,027 25,426,320 ( 91.12 %) 0 91.12 %

Shareholders

NameEquities%Valuation
Sofinnova Investments, Inc.
9.576 %
2,671,856 9.576 % 6 M $
Logos Global Management LP
7.169 %
2,000,460 7.169 % 4 M $
PFIZER, INC.
7.063 %
1,970,759 7.063 % 4 M $
OrbiMed Advisors Private Equity
4.544 %
1,268,013 4.544 % 3 M $
Millennium Management LLC
4.087 %
1,140,389 4.087 % 3 M $
Vanguard Group, Inc. (Subfiler)
3.238 %
903,624 3.238 % 2 M $
BlackRock Advisors LLC
2.987 %
833,515 2.987 % 2 M $
Cable Car Capital LLC
2.207 %
615,878 2.207 % 1 M $
Long Focus Capital Management LLC
1.993 %
556,105 1.993 % 1 M $
Acadian Asset Management LLC
1.750 %
488,440 1.750 % 1 M $

Company contact information

NextCure, Inc.

9000 Virginia Manor Road Suite 200

20705, Beltsville

+240 399 4900

http://www.nextcure.com
address NextCure, Inc.(NXTC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.44 USD
Average target price
5 USD
Spread / Average Target
+247.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NEXTCURE, INC. Stock NextCure, Inc.
+15.79% 40.28M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.10% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.80% 97.42B
ARGENX SE Stock argenx SE
+0.79% 22.2B
BIONTECH SE Stock BioNTech SE
-17.78% 21.23B
GENMAB A/S Stock Genmab A/S
-11.11% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.64% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.81% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.39% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. Company NextCure, Inc.